INFOS !
  • NEW ADDRESS: The management team of ERN-EYE is moving! Starting from March 19, you can find us at 1 Rue Eugène Boeckel, 67000 Strasbourg.

Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Accessibility

More about accessibility

Trouble using our website?
Contact us

Text logo ERN-EYE Tools
CPMS REDgistry Elearning Members area
Accessibility

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2

In this page

Clinical Trial

NCT03319849 Completed
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2

A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2

Phase 3
Interventional

Disease

Disease type

Paediatric clinical trials

Orphan drug recognition

NA

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

06/02/2018

Closing date

23/09/2022

Inclusion criteria :

More

Exclusion criteria :

More

Funding

industry

Members involved

Main investigators

Pr Thomas Reinhard

Substitute

Germany

Anterior Segment Rare Eye Diseases (WG4)
See more

Others investigators

Pr Daniel Böhringer

Representative

Germany

Anterior Segment Rare Eye Diseases (WG4)
Working Group Leader
See more

ERN EYE member investigating site

HCP : Principal investigators

More